Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Docetaxel + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
Tislelizumab | Tevimbra | BGB-A317|tislelizumab-jsgr | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Tevimbra (tislelizumab) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). Tevimbra (tislelizumab) is FDA-approved for use in patients with unresectable or metastatic esophageal squamous cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05189457 | Phase II | Docetaxel + Triptorelin Degarelix + Enzalutamide Enzalutamide + Triptorelin Docetaxel + Leuprolide Docetaxel + Relugolix Docetaxel + Goserelin Degarelix + Docetaxel Enzalutamide + Relugolix Enzalutamide + Goserelin Abiraterone + Leuprolide Docetaxel + Tislelizumab Enzalutamide + Leuprolide Abiraterone + Goserelin Abiraterone + Triptorelin Abiraterone + Degarelix Abiraterone + Relugolix | First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |